Bifogade filer
Kurs
+13,59%
Likviditet
303 MDKK
Kalender
Tid* | ||
2025-11-13 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-06 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-03-13 | N/A | Årsstämma |
2025-02-19 | 07:30 | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-05-03 | - | Kvartalsrapport 2024-Q1 |
2024-03-15 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2024-03-14 | - | Årsstämma |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-15 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-09 | - | Kvartalsrapport 2023-Q1 |
2023-03-20 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2023-02-03 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-11 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-03-28 | - | Split ALK B 1:20 |
2022-03-17 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2022-03-16 | - | Årsstämma |
2022-02-08 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-11 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | Kvartalsrapport 2021-Q1 |
2021-03-19 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2021-03-18 | - | Årsstämma |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-11-11 | - | Kvartalsrapport 2020-Q3 |
2020-08-12 | - | Kvartalsrapport 2020-Q2 |
2020-05-06 | - | Kvartalsrapport 2020-Q1 |
2020-03-12 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2020-03-11 | - | Årsstämma |
2020-02-05 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-13 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-03-14 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2019-03-13 | - | Årsstämma |
2019-02-07 | - | Bokslutskommuniké 2018 |
2018-11-09 | - | Kvartalsrapport 2018-Q3 |
2018-08-15 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | Kvartalsrapport 2018-Q1 |
2018-03-13 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
2018-03-12 | - | Årsstämma |
2018-02-06 | - | Bokslutskommuniké 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-08-16 | - | Kvartalsrapport 2017-Q2 |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-03-16 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2017-03-15 | - | Årsstämma |
2017-02-07 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-16 | - | Kvartalsrapport 2016-Q2 |
2016-05-04 | - | Kvartalsrapport 2016-Q1 |
2016-03-11 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2016-03-10 | - | Årsstämma |
2016-02-09 | - | Bokslutskommuniké 2015 |
2015-11-12 | - | Kvartalsrapport 2015-Q3 |
2015-08-18 | - | Kvartalsrapport 2015-Q2 |
2015-05-05 | - | Kvartalsrapport 2015-Q1 |
2015-03-13 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2015-03-12 | - | Årsstämma |
2015-02-09 | - | Bokslutskommuniké 2014 |
2014-11-14 | - | Kvartalsrapport 2014-Q3 |
2014-08-13 | - | Kvartalsrapport 2014-Q2 |
2014-05-08 | - | Kvartalsrapport 2014-Q1 |
2014-03-13 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2014-03-12 | - | Årsstämma |
2014-02-05 | - | Bokslutskommuniké 2013 |
2013-11-08 | - | Kvartalsrapport 2013-Q3 |
2013-08-14 | - | Kvartalsrapport 2013-Q2 |
2013-05-03 | - | Kvartalsrapport 2013-Q1 |
2013-03-13 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2013-03-12 | - | Årsstämma |
2013-02-05 | - | Bokslutskommuniké 2012 |
2012-11-12 | - | Kvartalsrapport 2012-Q3 |
2012-08-16 | - | Kvartalsrapport 2012-Q2 |
2012-05-10 | - | Kvartalsrapport 2012-Q1 |
2012-03-28 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2012-03-27 | - | Årsstämma |
2012-02-22 | - | Bokslutskommuniké 2011 |
2011-11-11 | - | Kvartalsrapport 2011-Q3 |
2011-08-16 | - | Kvartalsrapport 2011-Q2 |
2011-05-10 | - | Kvartalsrapport 2011-Q1 |
2011-04-04 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
2011-04-01 | - | Årsstämma |
2010-03-29 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Medicinteknik |
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated.
Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The full-year financial outlook has been updated mainly to reflect the recent development in European tablet sales.
The EBIT margin is still expected to improve to 17-19% but the earnings outlook now includes one-off costs of approximately DKK 60 million related to optimization initiatives, whereas no such costs were included in the original outlook from February 8, 2024.
ALK has decided to advance the release of its first quarter results. The Q1 report, originally due for 3 May 2024, will be published today, 2 May 2024. The previously announced presentation for investors and analysts will still take place on 3 May 2024 at 12:30 CET.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.